Annual CFO
-$81.07 M
-$49.20 M-154.40%
December 31, 2023
Summary
- As of March 13, 2025, STOK annual cash flow from operations is -$81.07 million, with the most recent change of -$49.20 million (-154.40%) on December 31, 2023.
- During the last 3 years, STOK annual CFO has fallen by -$38.85 million (-92.01%).
- STOK annual CFO is now -1405.70% below its all-time high of -$5.38 million, reached on December 31, 2017.
Performance
STOK Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$21.61 M
-$4.14 M-23.68%
September 30, 2024
Summary
- As of March 13, 2025, STOK quarterly cash flow from operations is -$21.61 million, with the most recent change of -$4.14 million (-23.68%) on September 30, 2024.
- Over the past year, STOK quarterly CFO has dropped by -$4.35 million (-25.22%).
- STOK quarterly CFO is now -166.53% below its all-time high of $32.49 million, reached on March 31, 2022.
Performance
STOK Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$84.31 M
-$4.35 M-5.44%
September 30, 2024
Summary
- As of March 13, 2025, STOK TTM cash flow from operations is -$84.31 million, with the most recent change of -$4.35 million (-5.44%) on September 30, 2024.
- Over the past year, STOK TTM CFO has dropped by -$1.52 million (-1.83%).
- STOK TTM CFO is now -4138.66% below its all-time high of -$1.99 million, reached on March 31, 2018.
Performance
STOK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
STOK Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -154.4% | -25.2% | -1.8% |
| 3 y3 years | -92.0% | -25.2% | -1.8% |
| 5 y5 years | -639.4% | -25.2% | -1.8% |
STOK Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -154.4% | at low | -166.5% | +12.0% | -490.4% | +3.7% |
| 5 y | 5-year | -161.0% | at low | -166.5% | +12.0% | -490.4% | +3.7% |
| alltime | all time | -1405.7% | at low | -166.5% | +12.0% | -4138.7% | +3.7% |
Stoke Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.61 M(+23.7%) | -$84.31 M(+5.4%) |
| Jun 2024 | - | -$17.48 M(-28.9%) | -$79.95 M(-5.1%) |
| Mar 2024 | - | -$24.57 M(+19.0%) | -$84.28 M(+4.0%) |
| Dec 2023 | -$81.07 M(+154.4%) | -$20.65 M(+19.6%) | -$81.07 M(-2.1%) |
| Sep 2023 | - | -$17.26 M(-20.8%) | -$82.79 M(-5.5%) |
| Jun 2023 | - | -$21.80 M(+2.1%) | -$87.58 M(+2.2%) |
| Mar 2023 | - | -$21.36 M(-4.5%) | -$85.71 M(+169.0%) |
| Dec 2022 | -$31.87 M(-52.4%) | -$22.37 M(+1.4%) | -$31.87 M(+23.7%) |
| Sep 2022 | - | -$22.06 M(+10.7%) | -$25.75 M(+40.1%) |
| Jun 2022 | - | -$19.93 M(-161.3%) | -$18.38 M(+28.7%) |
| Mar 2022 | - | $32.49 M(-299.8%) | -$14.28 M(-78.7%) |
| Dec 2021 | -$66.91 M | -$16.26 M(+10.7%) | -$66.91 M(+8.7%) |
| Sep 2021 | - | -$14.68 M(-7.3%) | -$61.58 M(+6.6%) |
| Jun 2021 | - | -$15.83 M(-21.4%) | -$57.77 M(+12.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$20.14 M(+84.2%) | -$51.59 M(+22.2%) |
| Dec 2020 | -$42.22 M(+36.0%) | -$10.93 M(+0.5%) | -$42.22 M(+1.8%) |
| Sep 2020 | - | -$10.87 M(+12.7%) | -$41.49 M(+7.3%) |
| Jun 2020 | - | -$9.65 M(-10.4%) | -$38.67 M(+9.6%) |
| Mar 2020 | - | -$10.77 M(+5.6%) | -$35.29 M(+13.6%) |
| Dec 2019 | -$31.05 M(+183.2%) | -$10.20 M(+26.8%) | -$31.05 M(+27.4%) |
| Sep 2019 | - | -$8.05 M(+28.3%) | -$24.37 M(+25.9%) |
| Jun 2019 | - | -$6.27 M(-3.9%) | -$19.36 M(+24.9%) |
| Mar 2019 | - | -$6.53 M(+85.8%) | -$15.51 M(+41.4%) |
| Dec 2018 | -$10.96 M(+103.6%) | -$3.52 M(+15.6%) | -$10.96 M(+47.2%) |
| Sep 2018 | - | -$3.04 M(+25.7%) | -$7.45 M(+69.0%) |
| Jun 2018 | - | -$2.42 M(+21.6%) | -$4.41 M(+121.6%) |
| Mar 2018 | - | -$1.99 M | -$1.99 M |
| Dec 2017 | -$5.38 M | - | - |
FAQ
- What is Stoke Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Stoke Therapeutics?
- What is Stoke Therapeutics annual CFO year-on-year change?
- What is Stoke Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Stoke Therapeutics?
- What is Stoke Therapeutics quarterly CFO year-on-year change?
- What is Stoke Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Stoke Therapeutics?
- What is Stoke Therapeutics TTM CFO year-on-year change?
What is Stoke Therapeutics annual cash flow from operations?
The current annual CFO of STOK is -$81.07 M
What is the all time high annual CFO for Stoke Therapeutics?
Stoke Therapeutics all-time high annual cash flow from operations is -$5.38 M
What is Stoke Therapeutics annual CFO year-on-year change?
Over the past year, STOK annual cash flow from operations has changed by -$49.20 M (-154.40%)
What is Stoke Therapeutics quarterly cash flow from operations?
The current quarterly CFO of STOK is -$21.61 M
What is the all time high quarterly CFO for Stoke Therapeutics?
Stoke Therapeutics all-time high quarterly cash flow from operations is $32.49 M
What is Stoke Therapeutics quarterly CFO year-on-year change?
Over the past year, STOK quarterly cash flow from operations has changed by -$4.35 M (-25.22%)
What is Stoke Therapeutics TTM cash flow from operations?
The current TTM CFO of STOK is -$84.31 M
What is the all time high TTM CFO for Stoke Therapeutics?
Stoke Therapeutics all-time high TTM cash flow from operations is -$1.99 M
What is Stoke Therapeutics TTM CFO year-on-year change?
Over the past year, STOK TTM cash flow from operations has changed by -$1.52 M (-1.83%)